Michael Goettler resigns from Bausch Health board effective June 30, 2026
Goettler is stepping down to become President and CEO of Knoa Pharma LLC, according to a company filing.
Bausch Health Companies Inc. said on July 1, 2026 that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.1
According to the company's 8-K filing, Goettler notified Bausch Health of his decision to resign from the Board on June 26, 2026, tied to his new role leading Knoa Pharma LLC.1
The company stated that the departure was unrelated to any dispute with Bausch Health over its operations, policies, or practices.1
John A. Paulson, Chairperson of the Bausch Health Board, commented on the departure, saying "We thank Michael for his valued service and wish him the best in his new role."1
The disclosure was made through a press release furnished as an exhibit to the Form 8-K. Per the filing, the press release dated July 1, 2026 announcing the resignation was furnished as Exhibit 99.1 to the Current Report and incorporated by reference.1
The filing also included standard corporate background. Bausch Health describes itself as a global, diversified pharmaceutical company that develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, operating through its controlling interest in Bausch + Lomb Corporation.1
The 8-K was signed by Seana Carson, Executive Vice President and General Counsel, and dated July 1, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.